Furthermore, CDK5 and HSD11B1 are therapeutic targets of preclinical (L-751250) and Phase 1 (AZD8329) drugs for obesity, respectively, and our results provide genetic support for early stage development (Additional file 2: Fig. S15). The gene discussed is HSD11B1; the disease is obesity disorder.